Analysts are estimating that Jazz Pharmaceuticals will report an earnings per share (EPS) of $5.43.
Jazz Pharmaceuticals bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
Overview of Past Earnings
Last quarter the company missed EPS by $1.91, which was followed by a 6.42% drop in the share price the next day.
Here's a look at Jazz Pharmaceuticals's past performance and the resulting price change:
Quarter
Q2 2025
Q1 2025
Q4 2024
Q3 2024
EPS Estimate
-6.34
4.66
5.81
5.50
EPS Actual
-8.25
1.68
6.60
6.61
Price Change %
-6.00
-9.00
3.00
7.00
Jazz Pharmaceuticals Share Price Analysis
Shares of Jazz Pharmaceuticals were trading at $138.38 as of November 03. Over the last 52-week period, shares are up 23.36%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analyst Views on Jazz Pharmaceuticals
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on ...
